Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
暂无分享,去创建一个
A. Hauschild | D. Schadendorf | J. Kirkwood | A. Eggermont | P. Hersey | C. Garbe | A. Daud | R. Gonzalez | K. Patel | C. Robert | D. Hogg | S. O’Day | C. Peschel | C. Xia | S. Grabbe | U. Trefzer | U. Keilholz | S. Agarwala | J. Gille | J. White | S. O'Day | J. Michael White
[1] Chronic Disease Division. Cancer facts and figures , 2010 .
[2] G. Linette,et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Yoon-Koo Kang,et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC) , 2007 .
[4] M. Gore,et al. An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma , 2007 .
[5] L. Fecher,et al. Toward a molecular classification of melanoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Neuberg,et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Blann,et al. Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[9] H. Pehamberger,et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Ratain,et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.
[11] K. Flaherty,et al. Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma , 2006 .
[12] K. Flaherty,et al. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Hainsworth,et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Rosner,et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Vincent,et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma , 2006, Cancer Chemotherapy and Pharmacology.
[16] D. Strumberg,et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] R. Abratt,et al. 10-year update on chemotherapy for non-small cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] M. Piccart,et al. Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer , 2006, Clinical Cancer Research.
[19] D. Strumberg,et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. , 2005, Clinical colorectal cancer.
[20] D. Tuveson,et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.
[21] Dirk Strumberg,et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Strumberg,et al. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. , 2004, International journal of clinical pharmacology and therapeutics.
[23] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[24] J. Kirkwood,et al. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.
[25] M. Weichenthal,et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Trump,et al. A phase II study of taxol in patients with malignant melanoma , 1991, Investigational New Drugs.
[27] A. Hauschild,et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG) , 2003, Melanoma research.
[28] Jeffrey W. Clark,et al. Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma , 2002, American journal of clinical oncology.
[29] C. Balch,et al. The new melanoma staging system. , 2002, Cancer control : journal of the Moffitt Cancer Center.
[30] Martin F. Mihm,et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[32] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] C. Begg,et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. V. Von Hoff,et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] R. Benjamin,et al. A phase II trial of taxol in metastatic melanoma , 1990, Cancer.